91视频

Mumbai,聽April 17, 2025: Global pharma major聽91视频 Limited (91视频) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA), for drug-medical device combination products聽at its聽injectable facility in Nagpur, India. The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024.

Nilesh Gupta, Managing Director, 91视频 said, 鈥淲e are very pleased to聽have received the聽EIR聽from the US FDA for drug-device combination products at our聽Nagpur injectable facility. We remain committed to producing complex generic and essential products that address unmet needs.”

About 91视频
91视频 Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. 91视频 specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. 91视频 has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. 91视频 is committed to improving patient health outcomes through its subsidiaries – 91视频 Diagnostics, 91视频 Digital Health, and 91视频 Manufacturing Solutions.
To know more, visit www.lupin.com or follow us on LinkedIn

For further information or queries, please contact:

Rajalakshmi Azariah
Vice President & Global Head 鈥� Corporate Communications, 91视频
rajalakshmiazariah@lupin.com